Attovia Therapeutics, Inc. (ATTO) earnings
Quarterly results of Attovia Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 6 quarters, the latest results release and when the next one is expected.
Latest quarter: Q3 FY2026
In Q3 FY2026 (ended September 30, 2026) Attovia Therapeutics, Inc. reported revenue of $0 and a net loss of $22.3M.
Diluted earnings per share were -$0.76.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | $0 | - | -$22.3M | -$0.76 |
| Q2 FY2026 | $450K | - | -$20.7M | -$4.88 |
| Q2 FY2026 | - | - | -$18.7M | - |
| Q3 FY2026 | $360K | - | -$13.8M | -$3.44 |
| Q2 FY2026 | $0 | - | -$14.4M | -$3.71 |
| Q2 FY2026 | - | - | -$15.2M | - |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
What were Attovia Therapeutics, Inc.'s latest quarterly results?
For Q3 FY2026, which ended September 30, 2026, Attovia Therapeutics, Inc. reported revenue of $0 and a net loss of $22.3M. The figures come from its filing with the SEC.
Get an email when ATTO reports
Follow ATTO and we email you its next results the day they are filed, with the numbers explained.